Use of intravenous iron supplementation in chronic kidney disease: Interests, limits, and recommendations for a better practice;Utilisation des dérivés injectables du fer au cours de la maladie rénale chronique: intérêts, limites et conseils pour un bon usage

Nephrologie et Therapeutique

Volumn 11, Issue 7, 2015, Pages 531-542

  Rottembourg, Jacques ^a   Rostoker, Guy ^b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Hôpital Privé Claude Galien   (France)

Author keywords

Allergic reactions; Chronic kidney disease; Hemosiderosis; Intravenous iron; Iron complexes; Oral iron; Oxydative stress

Indexed keywords

ANTIANEMIC AGENT; FERRIC CARBOXYMALTOSE; HEMOGLOBIN; IRON; IRON DEXTRAN; IRON SACCHARATE; IRON DERIVATIVE;

ARTICLE; CHRONIC KIDNEY DISEASE; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON DEFICIENCY ANEMIA; IRON STORAGE; VITAMIN SUPPLEMENTATION; ANEMIA, IRON-DEFICIENCY; COMPLICATION; DIETARY SUPPLEMENT; HEMODIALYSIS; INTRAVENOUS DRUG ADMINISTRATION; PRACTICE GUIDELINE; RENAL INSUFFICIENCY, CHRONIC;

ANEMIA, IRON-DEFICIENCY; DIETARY SUPPLEMENTS; GUIDELINES AS TOPIC; HUMANS; INJECTIONS, INTRAVENOUS; IRON COMPOUNDS; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84949559576     PISSN: 17697255     EISSN: 18729177     Source Type: Journal    
DOI: 10.1016/j.nephro.2015.04.009     Document Type: Short Survey

References (72)

1. New recommendations to manage risk of allergic reactions with intravenous iron-containing medicines. EMA-CHMP; 2013 [EMA/377372/2013]
2. Ministère des Affaires sociales et de la Santé. Circulaire no DGOS/DGS/PP2/ 2014 du 30 janvier 2014 relative aux modalités d'utilisation des spécialités abase de fer IV injectable
3. Fishbane S. Iron management in non-dialysis-dependent CKD. Am J Kidney Dis 2007;49:736-43
4. Handelman GJ, Levin NW. Iron and anemia in human biology: a review of mechanisms. Heart Fail Rev 2008;13:393-404
5. Gantz T, Nemeth E. Iron sequestration and anemia of inflammation. Semin Hematol 2009;46:387-93
6. Rottembourg JB, Dansaert A. Faisabilitéde la stratégie d'administration de la darbepoetin alfa tous les quinze jours : expérience 2005-2007 d'un centre de dialyse. Nephrol Ther 2011;7:549-57
7. Fishbane S, Pollack S, Felfman HI, Joffe MM. Iron indices in chronic kidney diseases in the National Health and Nutritional Examination Survey 1988- 2004. Clin J Am Soc Nephrol 2009;4:57-61
8. Mercadal L, Metzger M, Haymann JP, Thervet E, Boffa JJ, Flamant M, et al. A 3- marker index improves the identification of iron disorders in CKD anaemia. PLOS One 2014;9:e48414
9. Joshi AD, Holdford DA, Brophy DF, Haye SE, Mays D, Gehr TWB. Utilization patterns of IV iron and erythropoiesis-stimulating agents in anemic chronic kidney disease patients: a multihospital study. Anemia 2012 [Article ID 248430 ; 11 p]
10. World Health Organization. WHO Guidelines for the use of iron supplements to prevent and treat iron deficiency. Anemia. WHO/NHD; 2001 [Available from http://www.who.int/nutrition/Publications/micronutrients/guidelines-for-iron-supplementation.pdf]
11. Kidney Disease Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl 2012;2:279-335
12. Locatelli P, Barany P, Covic A, et al. Kidney disease: improving global outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrol Dial Transplant 2013;28: 1346-59
13. Rostoker G, Hummel A, Chantrel F, Ryckelynck JP. Actualité s sur la prise en charge de l'anémie et de la carence martiale du dialyse. Nephrol Ther 2014;10: 221-7
14. Ali M, Rigolosi R, Fayemi AO, Braun EV, Frascino J, Singer R. Failure of serum ferritin levels to predict bone-marrow iron content after intravenous iron-dextran therapy. Lancet 1982;1:652-5
15. Drüeke TB, Parfrey PS. Summary of the KDIGO guideline on anemia and comment: reading between the (guide) line(s). Kidney Int 2012;82:952-60
16. Becker W, Branco F, Brasseur D, Bresson JL, Flynn A, Jackson A, et al. Opinion of the scientific panel on dietetic products, nutrition, and allergies on a request from the commission related to the tolerable upper intake level of iron (request no. EFSA-Q-20013-018). EFSA J 2004;125:1-34
17. Beaumont C, Karim Z. Actualité du métabolisme du fer. Rev Med Interne 2013;34:17-25
18. Elftheriadiadis T, Liakopoulos V, Antoniadi G, Kartsios C, Stefanidis I. The role of hepcidin in iron homeostasis and anemia in hemodialysis patients. Semin Dial 2009;22:70-7
19. Larson D, Coyne DW. Understanding and exploiting hepcidin as an indicator of anemia due to chronic kidney disease. Kidney Res Clin Pract 2013;32:11-5
20. Valenti L, Messa P, Pelusi S, Campostrini N, Girelli D. Hepcidin levels in chronic hemodialysis patients: a critical evaluation. Clin Chem Lab Med 2014;52:613-9
21. Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet 2014;46:678-84
22. Srai SK, Chung B, Marks J, Pourvali K, Solanky N, Rapisarda C, et al. Erythro-poetin regulates intestinal iron absorption in a rat model of chronic renal failure. Kidney Int 2010;78:660-7
23. Stefanidis I, Liakopoulos V, Kapsoritakis AN, Ionnidis I. Gastric antral vascular ectasia (watermelon stomach) in patients with ESRD. Am J Kidney Dis 2006;47:77-82
24. Sargent JA, Acchiardo SR. Iron requirements in hemodialysis. Blood Purif 2004;22:112-23
25. Otti T, Khajehdehi P, Fawzy A, Gellens M, Bastani B. Comparison of blood loss with different high-flux and high-efficiency hemodialysis membranes. Am J Nephrol 2001;21:16-9
26. Kalocheretis P, Vlamis I, Belesi C, Makriniotou I, Zerbala S, Savidou E, et al. Residual blood loss in single use dialyzers: effect of different membranes and flux. Int J Artif Organs 2006;29:286-92
27. Rottembourg JB, Kpade F, Tebibel F, Dansaert A, Chenuc G. Stable hemoglobin in hemodialysis patients: forest for the trees- a 12-week pilot observational study. BMC Nephrol 2013;14:343
28. Canaud B, Chenine L, Henriet D, Leray H. Optimal management of central venous catheters for hemodialysis. Contrib Nephrol 2008;161:39-47
29. Wong G, Li MWY, Howard K, Hua DK, Chapman JR, Bourke M, et al. Health benefits and costs of screening for colorectal cancer in people on dialysis or who have received a kidney transplant. Nephrol Dial Transplant 2013;28:917-26
30. Rosenblatt SG, Drake S, Fadem S, Welch R, Lifschitz MD. Gastrointestinal blood loss in patients with chronic renal failure. Am J Kidney Dis 1982;1:232-6
31. Flint S, Taylor E, Beavis J, Becker GJ, Pedagogos E. Increased iron requirement in hemodialysis patients on antiplatelet agents or warfarin. Nephron Clin Pract 2009;113:c38-45
32. Alleyne M, Horne MK, Miller JL. Individualized treatment for iron-deficiency anemia in adults. Am J Med 2008;121:943-8
33. Agence nationale de sé curité du médicament et des produits de santé (ANSM). Traitement de l'anémie des hémodialysé s par solutions de fer IV : l'ANSM rappelle la né cessité de respecter les schémas posologiques de l'AMM. Point d'information du 18 fé vrier 2013
34. Besarab A, Coyne DW. Iron supplementation to treat anemia in patients with chronic kidney disease. Nat Rev Nephrol 2010;6:699-710
35. Geisser P, Baer M, Schaub E. Structure/histoxicity relationship of parenteral iron preparations. Arzneimittelforschung 1992;42:1439-52
36. Barton Pai A, Boyd AV, McQuade CR, Harford A, Norenberg JP, Zager PG. Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis. Pharmacotherapy 2007;27:343-50
37. Toblli JE, Cao G, Oliveri L, Angerosa M. Comparison of the renal, cardiovascular, and hepatic toxicity data of original intravenous compounds. Nephrol Dial Transplant 2010;25:3631-40
38. Toblli JE, Cao G, Oliveri L, Angerosa M. Differences between the original iron sucrose complex Venofer1 and the iron sucrose similar Generis1 and poten-tial implications. Port J Nephrol Hypert 2009;23:53-63
39. Rottembourg J, Kadri A, Leonard E, Dansaert A, Lafuma A. Do two intravenous iron sucrose preparations have the same efficacy? Nephrol Dial Transplant 2011;26:3262-7
40. Martin-Malo A, Merino A, Carracedo J, Alvarez-Lara MA, Ojeda R, Soriano S, et al. Effects of intravenous iron on mononuclear cells during the haemodia-lysis session. Nephrol Dial Transplant 2012;27:2465-71
41. Stein J, Dignass A, Chow KU. Clinical case reports raise doubts about the therapeutic equivalence of an iron sucrose similar preparation compared with iron sucrose originator. Curr Med Res Opin 2012;28:241-3
42. Lee ES, Park BR, Kim JS, Choi GY, Lee JJ. Comparison of adverse events profile of intravenous iron sucrose and iron sucrose similar in postpartum and gyneco-logic operative patients. Curr Med Res Opin 2013;29:141-7
43. Beshara S, Sörensen J, Lubberink M, Tolmachev V, Langström B, Antoni G, et al. Pharmacokinetics and red cell utilization of 52Fe/59Fe labelled iron poly-maltose in anaemic patients using positron emission tomography. Br J Hae-matol 2003;120:853-9
44. National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. 3.2. Using iron agents. Am J Kidney Dis 2006;47:S58-70
45. Yamamoto H, Tsubakihara Y. Limiting iron supplementation for anemia in dialysis patients: the basis for Japan's conservative guidelines. Semin Dial 2011;24:269-71
46. Qunibi WY, Martinez C, Smith M, Benjamin J, Mangione A, Roger SD. A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients. Nephrol Dial Transplant 2011; 26:1599-607
47. Agarwal R, Rizkala AR, Basani B, Kaskas MO, Leehey DJ, Besarab A. A random-ized controlled trial of oral versus inravenous iron in chronic kidney disease. Am J Nephrol 2006;26:445-54
48. Van Wyck DB, Roppolo M, Martinez CO, Mazey RM, McMurray S, United Iron Sucrose (Venofer) Clinical Trials Group. A randomized, controlled trial com-paring IV iron sucrose to oral iron in anaemic patients with non-dialysis-dependent CKD. Kidney Int 2005;68:2846-56
49. Mace TA, Syed A, Bhandari S. Iron (III) isomaltoside 1000. Expert Rev Hematol 2013;6:239-46
50. Macdougall IC, Bock AH, Carrera F, Eckardt KU, Gaillard C, VanWyck D, et al. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant 2014;29:2075-84
51. Macdougall IC. Iron supplementation in the non dialysis chronic kidney disease (ND-CKD) patient oral or intravenous? Curr Med Res Opin 2010;26: 473-82
52. Mircescu G, Garneata L, Capusa C, Ursea N. Intravenous iron supplementation for the treatment of anaemia in pre-dialyzed chronic renal failure. Nephrol Dial Transplant 2006;21:120-4
53. Fievet P, Coppin M, Brazier F, Lefèvre M, Stephan R, Demontis R. Traitement de la carence martiale en pré -dialyse par l'administration intraveineuse de doses é levé es de fer dextran de bas poids molé culaire. Nephrol Ther 2012;8:41-6
54. Rottembourg J, Sonigo Y, Dansaert A, Diaconita M, Guerin A. La prise en charge de l'anémie et de ses conséquences chez les patients débutant l'hémodialyse : importance du fer intraveineux en pré -dialyse. Nephrol Ther 2013;9:486-93
55. Coyne DW, Kapoian T, Suki W, Singh AK, Moran JE, Dahl NV, et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 2007;18:975-84
56. Kosch M, Bahner U, Bettger H, Matzkies F, Teschner M, Schaefer RM. A randomized controlled parallel-group trial on efficacy and safety of iron sucrose (Venofer) vs iron gluconate (Ferrlecit) in haemodialysis patients treated with rHuEpo. Nephrol Dial Transplant 2001;16:1239-44
57. Sing H, Reed J, Noble S, Cangiano JL, Van Wyck DB, United States Iron Sucrose (Venofer) Clinical Trials Group. Effect of intravenous iron sucrose in peritoneal dialysis patients who receive erythropoiesis-stimulating agents for anemia: a randomized controlled trial. Clin J Am Soc Nephrol 2006;1:475-82
58. Rozen-Zvi B, Grafter-Gvili A, Paul M, Leibovici L, Shpielberg O, Grafter U. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis. Am J Kidney Dis 2008;52: 897-906
59. MacDougall IC, Tucker B, Thompson J, Tomson CR, Baker LR, Raine AE. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996;50:1694-9
60. Kapoian T, O'Mara NB, Singh AK, Moran J, Rizkala AR, Geronemus R, et al. Ferric gluconate reduces epoetin requirements in hemodialysis patients with ele-vated ferritin. J Am Soc Nephrol 2008;19:372-9
61. Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoi-etin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 1995;26:41-6
62. Wiksröm B, Bandhari S, Barani P, Kalra PA, Ladefoged S, Wilske J, et al. Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease. J Nephrol 2011;24:589-96
63. Nissenson AR, Lindsay RM, Swan S, Seligman P, Strobos J. Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients. North American Clinical Trial. Am J Kidney Dis 1999;33:471-82
64. Coulon S, Dussiot M, Grapton D, Trovati-Maciel T, Huey Mei Wang P. Polymeric IgA1 controls erythroblast proliferation and accelerates erythropoiesis recov-ery in anemia. Nature 2011;17:1456-66
65. Vaziri ND. Epidemic of iron overload in dialysis population caused by intra-venous iron products: a plea for moderation. Am J Med 2012;125:951-2
66. Rostoker G, Griuncelli M, Loridon C, Couprie R, Benmaadi A, Bounhiol C, et al. Hemodialysis-associated hemosiderosis in the era of erythropoiesis-stimulat-ing agents: a MRI study. Am J Med 2012;125:991-9
67. Beshara S, Lundqvist H, Sundin J, Lubberink M, Tolmachev V, Valind S, et al. Pharmacokinetic and red cell utilization of iron (III) hydroxide-sucrose complex in anaemic patients: a study using positron emission tomography. Br J Haematol 1999;104:296-302
68. Rostoker G, Cohen Y. MRI repercussions of intravenous iron products used for iron-deficiency anemia and dialysis-associated anemia. J Comput Assist Tomogr 2014;38:843-4
69. Ring G, Messmer K. Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet 1977;309:466-9
70. Chertow GM, Mason P, Vaage-Nilsen O, Ahlmen J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 2006;21: 378-82
71. Bailie GR. Comparison of rates of reported adverse events associated with i.v iron products in the United States. Am J Health Syst Pharm 2012;69: 310-20
72. KDIGO Controversies conference on iron management in chronic kidney disease. Kidney Int 2015;(Suppl.) [in press]